Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes

Abstract

Aims: Examine barriers for taking glucose-lowering oral medications, associated baseline characteristics, strategies used, and the adherence impact in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study.

Methods: We studied youth prescribed oral diabetes medications over two years (N = 611, 583, and 525 at 6, 12, and 24 months). Clinicians documented barriers (e.g. forgetting, routines, other concerns) in the subsample that reported missed doses (N = 423 [69.2%], 422 [72.4%], and 414 [78.9%] at 6, 12, and 24 months, respectively). Adherence strategies were also assessed (e.g. family, schedule, reminder device) using standard questions. Logistic regression was used to analyze associations with medication adherence.

Results: Those missing doses were not different from the total sample (61.5% female, 13.9 ± 2.0 years, >80% racial/ethnic minorities). No baseline demographic or clinical predictors of barriers to medication adherence were identified. Among those for whom barriers were assessed, "forgetting" with no reason named (39.3%) and disruptions to mealtime, sleep, and schedule (21.9%) accounted for the largest proportion of responses. Family support was the primary adherence strategy identified by most youth (≥50%), followed by pairing the medication regimen with daily routines (>40%); the latter strategy was associated with significantly higher adherence rates (p = 0.009).

Conclusions: Family supported medication adherence was common in this mid-adolescent cohort, but self-management strategies were also in evidence. Findings are similar to those reported among youth with other serious chronic diseases. Prospective studies of multi-component family support and self-management interventions for improving medication adherence are warranted.

Trial registration: ClinicalTrials.gov NCT00081328.

Conflict of interest statement

Conflicts of Interest: EMV has no conflicts of interest to disclose. LD serves on the Eli Lilly Advisory Board. LLK is a consultant for Takeda Pharmaceuticals. NWA is a consultant for Daiichi-Sankyo. PMY received a speaker stipend from Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.

Funding Support and Conflict of Interest Disclosures: Reported following Conclusion.

Copyright © 2018 Elsevier B.V. All rights reserved.